AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23889978 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 0
Study 19900212 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 326
Study 19900212 — intervention group
Group type: COMPARATOR
Intervention: Non-prostaglandin therapy (non-PGs)
Number of subjects: 326
Study 19900212 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost and Non-prostaglandin therapy (non-PGs)
Number of subjects: 326
Study 18213621 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant and adjuvant temozolomide (TMZ)
Number of subjects: 219
Study 18213621 — intervention group
Group type: COMPARATOR
Intervention: Initial radiotherapy alone
Number of subjects: 219
Study 16996288 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 9
Study 16996288 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate diet
Number of subjects: 9
Study 15019894 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg once daily for 3 weeks before and 6 weeks after electrical cardioversion
Number of subjects: 114
Study 15019894 — intervention group
Group type: COMPARATOR
Intervention: No drug in addition to standard therapy
Number of subjects: 114
Study 11705559 — intervention group
Group type: EXPERIMENTAL
Intervention: MaxSTE (ST-segment deviation in the single ECG lead with maximum deviation)
Number of subjects: 2719
Study 11705559 — intervention group
Group type: EXPERIMENTAL
Intervention: SumSTR (sum of early resolution of ST-segment elevation)
Number of subjects: 2719
Study 9057509 — intervention group
Group type: EXPERIMENTAL
Intervention: Multishot echoplanar MR imaging (EPI)
Number of subjects: 26
Study 9057509 — intervention group
Group type: COMPARATOR
Intervention: Fast spin-echo MR imaging
Number of subjects: 26
Study 8221559 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-epidoxorubicin-cyclophosphamide (CEP) chemotherapy alone
Number of subjects: 182
Study 8221559 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-epidoxorubicin-cyclophosphamide (CEP) plus recombinant alpha-2-IFN
Number of subjects: 182
Study 3476650 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride with epinephrine
Number of subjects: 0
Study 3476650 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine with epinephrine
Number of subjects: 0
Study 31569155 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine-disrupting chemicals (EDCs)
Number of subjects: 50
Study 31569155 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent EDCs
Number of subjects: 50
Study 31569155 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpersistent EDCs
Number of subjects: 50
Study 31569155 — intervention group
Group type: EXPERIMENTAL
Intervention: Five persistent chemicals
Number of subjects: 50
Study 29425398 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Management Training‐Oregon Model (PMTO)
Number of subjects: 0
Study 29425398 — intervention group
Group type: EXPERIMENTAL
Intervention: Child therapy
Number of subjects: 0
Study 29425398 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice group
Number of subjects: 0
Study 29425398 — intervention group
Group type: COMPARATOR
Intervention: No-choice group
Number of subjects: 0
Study 27891568 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured text message giving reassurance
Number of subjects: 84
Study 27891568 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured telephone call
Number of subjects: 84
Study 27891568 — intervention group
Group type: COMPARATOR
Intervention: Control group (no post-procedure communication)
Number of subjects: 84
Study 24749354 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestically produced Salbutamol Sulfate Aerosol MDI (200 microg single-dose)
Number of subjects: 238
Study 24749354 — intervention group
Group type: COMPARATOR
Intervention: Imported Salbutamol Sulfate Aerosol MDI (200 microg single-dose)
Number of subjects: 238
Study 23194103 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home health consultation program (HCP) with four in-home visits and three phone calls from APNs
Number of subjects: 461
Study 19164490 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 21
Study 19164490 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 21
Study 18583000 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician peer educator intervention during VFC visit
Number of subjects: 73
Study 18583000 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician peer educator intervention
Number of subjects: 73
Study 18583000 — intervention group
Group type: COMPARATOR
Intervention: VFC visits
Number of subjects: 73
Study 15966702 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal bioadhesive nystatin tablet (100,000 IU per tablet) applied daily
Number of subjects: 19
Study 15966702 — intervention group
Group type: COMPARATOR
Intervention: Conventional local cleaning with oral nystatin suspension on a brush
Number of subjects: 19
Study 15966702 — intervention group
Group type: COMPARATOR
Intervention: No antimicrobial agents (Control group)
Number of subjects: 19
Study 12366489 — intervention group
Group type: EXPERIMENTAL
Intervention: Total abdominal hysterectomy
Number of subjects: 30
Study 12366489 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal abdominal hysterectomy
Number of subjects: 30
Study 12366489 — intervention group
Group type: COMPARATOR
Intervention: Total and subtotal abdominal hysterectomy
Number of subjects: 30
Study 9445494 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine (d4T) 1 mg/kg orally every 12 hours, maximum 40 mg orally every 12 hours
Number of subjects: 212
Study 9445494 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV, AZT) 180 mg/m2 orally every 6 hours, maximum 200 mg orally every 6 hours
Number of subjects: 212
Study 7599909 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone (1 g, 3 times/day for 2 days, followed by twice 1 g on day 3)
Number of subjects: 12
Study 7599909 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (50 mg, 3 times/day for 2 days, followed by twice 50 mg on day 3)
Number of subjects: 12
Study 7599909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2369315 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil therapy (500 mg/m2 per day) by portal vein infusion for 7 days
Number of subjects: 224
Study 2369315 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 224
Study 2369315 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil therapy
Number of subjects: 224
Study 327057 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 20
Study 327057 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 20
Study 327057 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined doses of Fenfluramine and Dextroamphetamine
Number of subjects: 20
Study 327057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 327057 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdrug changes
Number of subjects: 20
Study 31895437 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride for 8 weeks
Number of subjects: 221
Study 31895437 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 221
Study 31895437 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Sertraline and Placebo)
Number of subjects: 221
Study 31511044 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine-enriched essential amino acid (L-EAA) supplementation (5 g L-EAA five times per day for up to 14 days)
Number of subjects: 8
Study 31511044 — intervention group
Group type: COMPARATOR
Intervention: Standard feed only (control group)
Number of subjects: 8
Study 28045286 — intervention group
Group type: EXPERIMENTAL
Intervention: panic‐focused psychodynamic psychotherapy, cognitive‐behavioral therapy, or applied relaxation therapy (24 twice‐weekly sessions)
Number of subjects: 130
Study 26283667 — intervention group
Group type: EXPERIMENTAL
Intervention: AVERT intervention (specific details not provided)
Number of subjects: 1158
Study 23849242 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise and psycho-education intervention (EP)
Number of subjects: 161
Study 23849242 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise only (E)
Number of subjects: 161
Study 23849242 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition (WLC)
Number of subjects: 161
Study 21266669 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (500 mg)
Number of subjects: 19
Study 21266669 — intervention group
Group type: COMPARATOR
Intervention: Metabolic syndrome serum
Number of subjects: 19
Study 21266669 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin immunodepletion
Number of subjects: 19
Study 21266669 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (5-500 μM)
Number of subjects: 19
Study 19860922 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 2 white bean extract (powder) at 3000 mg
Number of subjects: 13
Study 19860922 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 2 white bean extract (capsule) at 2000 mg
Number of subjects: 13
Study 19860922 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 2 white bean extract (capsule) at 3000 mg
Number of subjects: 13
Study 19860922 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 2 white bean extract (powder) at 1500 mg
Number of subjects: 13
Study 19860922 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 2 white bean extract (powder) at 2000 mg
Number of subjects: 13
Study 19860922 — intervention group
Group type: COMPARATOR
Intervention: White bread (control)
Number of subjects: 13
Study 16601747 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser capsulotomy (YLC)
Number of subjects: 158
Study 15217941 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 with food (35 mg/m2)
Number of subjects: 18
Study 15217941 — intervention group
Group type: COMPARATOR
Intervention: S-1 without food (35 mg/m2)
Number of subjects: 18
Study 11209118 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg/day for 12 weeks
Number of subjects: 101
Study 11209118 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole (pulse) 200 mg twice a day for 1 week, given for 3 pulses
Number of subjects: 101
Study 11263297 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive p53 expression in advanced stage NSCLC
Number of subjects: 137
Study 11263297 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Hras expression
Number of subjects: 137
Study 11263297 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal DI and PI
Number of subjects: 137
Study 11263297 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression rates of c-erbB2 and PCNA
Number of subjects: 137
Study 8067598 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of fluticasone propionate once daily
Number of subjects: 416
Study 8067598 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of fluticasone propionate twice daily
Number of subjects: 416
Study 8067598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study 2897912 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium (single bolus 0.95 mg kg‐1)
Number of subjects: 80
Study 2897912 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (single bolus 0.53 mg kg‐1)
Number of subjects: 80
Study 2897912 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (single bolus 0.07 mg kg‐1)
Number of subjects: 80
Study 2897912 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium (divided doses 0.15 mg kg‐1, 3 min before 0.08 mg kg‐1)
Number of subjects: 80
Study 2897912 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (divided doses 0.07 mg kg‐1, 3 min before 0.46 mg kg‐1)
Number of subjects: 80
Study 2897912 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (divided doses 0.01 mg kg‐1, 3 min before 0.06 mg kg‐1)
Number of subjects: 80
Study 2897912 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine (1 mg kg‐1)
Number of subjects: 80
Study 1093330 — intervention group
Group type: EXPERIMENTAL
Intervention: Sch 1000 (Atrovent) 0.02 mg
Number of subjects: 12
Study 1093330 — intervention group
Group type: EXPERIMENTAL
Intervention: Sch 1000 (Atrovent) 0.08 mg
Number of subjects: 12
Study 1093330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30882777 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-immersed perspective
Number of subjects: 0
Study 30882777 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-person perspective
Number of subjects: 0
Study 30882777 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemplar perspective
Number of subjects: 0
Study 28544460 — intervention group
Group type: EXPERIMENTAL
Intervention: Inogen One G2 POC
Number of subjects: 20
Study 28544460 — intervention group
Group type: COMPARATOR
Intervention: Oxygen cylinder
Number of subjects: 20
Study 28544460 — intervention group
Group type: EXPERIMENTAL
Intervention: EverGo POC
Number of subjects: 20
Study 26109589 — intervention group
Group type: EXPERIMENTAL
Intervention: apixaban (5 mg twice daily)
Number of subjects: 7392
Study 26109589 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7392
Study 23886150 — intervention group
Group type: EXPERIMENTAL
Intervention: CIK cell therapy (5 courses over 18 months)
Number of subjects: 0
Study 23886150 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CIK cell therapy)
Number of subjects: 0
Study 22779193 — intervention group
Group type: EXPERIMENTAL
Intervention: Naoxintong capsule
Number of subjects: 0
Study 22779193 — intervention group
Group type: COMPARATOR
Intervention: Tongxinluo capsule (Control)
Number of subjects: 0
Study 18547693 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a chart for extraction instruments and techniques
Number of subjects: 0
Study 18547693 — intervention group
Group type: COMPARATOR
Intervention: No chart for extraction instruments and techniques (control)
Number of subjects: 0
Study 17290150 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (n = 7)
Number of subjects: 13
Study 17290150 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 13
Study 14978787 — intervention group
Group type: EXPERIMENTAL
Intervention: Right prefrontal slow repetitive transcranial magnetic stimulation (rTMS) at 1 Hz
Number of subjects: 0
Study 14978787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11380463 — intervention group
Group type: COMPARATOR
Intervention: Standard ADE (cytarabine, daunorubicin, etoposide)
Number of subjects: 235
Study 11380463 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential ADE (cytarabine, daunorubicin, etoposide)
Number of subjects: 235
Study 11380463 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSA)
Number of subjects: 235
Study 11380463 — intervention group
Group type: COMPARATOR
Intervention: Standard ADE
Number of subjects: 235
Study 11380463 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential ADE
Number of subjects: 235
Study 11380463 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 235
Study 9425485 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI scanning
Number of subjects: 9
Study 8536027 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg pethidine (i. art.) in 50 ml saline
Number of subjects: 30
Study 8536027 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg pethidine + 200 micrograms adrenaline (i. art.) in 50 ml saline
Number of subjects: 30
Study 8536027 — intervention group
Group type: COMPARATOR
Intervention: 250 mg prilocaine + 200 micrograms adrenaline (i. art.) in a volume of 50 ml
Number of subjects: 30
Study 3691607 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute AMI 50 mg
Number of subjects: 12
Study 3691607 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP
Number of subjects: 12
Study 3691607 — intervention group
Group type: EXPERIMENTAL
Intervention: Subchronic AMI + acute BUP
Number of subjects: 12
Study 3691607 — intervention group
Group type: EXPERIMENTAL
Intervention: Subchronic AMI
Number of subjects: 12
Study 3691607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29618459 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile van diagnostic evaluation
Number of subjects: 200
Study 29618459 — intervention group
Group type: COMPARATOR
Intervention: Central hospital diagnostic evaluation
Number of subjects: 200
Study 29618459 — intervention group
Group type: EXPERIMENTAL
Intervention: Colposcopy
Number of subjects: 200
Study 29618459 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo microscopy
Number of subjects: 200
Study 27272084 — intervention group
Group type: EXPERIMENTAL
Intervention: Face cream containing 4-Hexyl-1, 3-phenylenediol and ascorbic acid-2 glucoside
Number of subjects: 42
Study 27272084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 24407192 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic radical cystectomy (LRC)
Number of subjects: 70
Study 24407192 — intervention group
Group type: COMPARATOR
Intervention: Open radical cystectomy (ORC)
Number of subjects: 70
Study 23796764 — intervention group
Group type: EXPERIMENTAL
Intervention: Ahmed implant
Number of subjects: 238
Study 23796764 — intervention group
Group type: COMPARATOR
Intervention: Baerveldt implant
Number of subjects: 238
Study 20670842 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma UCN‐1 >or=12.1 pM
Number of subjects: 154
Study 20670842 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma ET‐1 >or=2.29 pM
Number of subjects: 154
Study 20670842 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of UCN‐1 and ET‐1
Number of subjects: 154
Study 18690760 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day
Number of subjects: 106
Study 18690760 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg/day
Number of subjects: 106
Study 18690760 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 106
Study 16160867 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (0.4 IU/kg)
Number of subjects: 36
Study 16160867 — intervention group
Group type: EXPERIMENTAL
Intervention: NPH insulin (0.4 IU/kg)
Number of subjects: 36
Study 16160867 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin ultralente (0.4 IU/kg)
Number of subjects: 36
Study 12646833 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel (HS)
Number of subjects: 117
Study 12646833 — intervention group
Group type: COMPARATOR
Intervention: Conventional electrocautery (EC)
Number of subjects: 117
Study 14615229 — intervention group
Group type: EXPERIMENTAL
Intervention: Various electrocardiographic analysis techniques (Fourier analysis, Correlation Dimension Estimation, Approximate Entropy, Discrete Wavelet Transform)
Number of subjects: 0
Study 14615229 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic recordings (approximately 2h in length)
Number of subjects: 0
Study 14615229 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of different analysis methods
Number of subjects: 0
Study 10221603 — intervention group
Group type: EXPERIMENTAL
Intervention: Gasless laparoscopy
Number of subjects: 103
Study 10221603 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy with pneumoperitoneum
Number of subjects: 103
Study 7530834 — intervention group
Group type: COMPARATOR
Intervention: WHO-ORS
Number of subjects: 144
Study 7530834 — intervention group
Group type: EXPERIMENTAL
Intervention: Amylyte-ORS
Number of subjects: 144
Study 2375670 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback followed by PET
Number of subjects: 0
Study 2375670 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback followed by NMS
Number of subjects: 0
Study 2375670 — intervention group
Group type: EXPERIMENTAL
Intervention: NMS followed by PET
Number of subjects: 0
Study 2375670 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 weeks of PET
Number of subjects: 0
Study 2375670 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 863617 — intervention group
Group type: EXPERIMENTAL
Intervention: Weicon 72
Number of subjects: 0
Study 863617 — intervention group
Group type: COMPARATOR
Intervention: Weicon 38
Number of subjects: 0
Study 28236777 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan of the axilla on the same side as the breast cancer
Number of subjects: 291
Study 28236777 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 291
Study 26245776 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam (medium and high dosage)
Number of subjects: 194
Study 26245776 — intervention group
Group type: COMPARATOR
Intervention: Clobazam (low dosage)
Number of subjects: 194
Study 26245776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 23384975 — intervention group
Group type: EXPERIMENTAL
Intervention: Compounded estrogen cream (Bi‐est (80:20); 2.0 mg) + compounded oral progesterone 100 mg
Number of subjects: 40
Study 23384975 — intervention group
Group type: EXPERIMENTAL
Intervention: Compounded estrogen cream (Bi‐est (80:20); 2.5 mg) + compounded oral progesterone 100 mg
Number of subjects: 40
Study 23384975 — intervention group
Group type: EXPERIMENTAL
Intervention: Compounded estrogen cream (Bi‐est (80:20); 3.0 mg) + compounded oral progesterone 100 mg
Number of subjects: 40
Study 21279864 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg · kg(‐1) body weight) after a 4-day withdrawal period
Number of subjects: 12
Study 21279864 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg · kg(‐1) body weight) without a withdrawal period
Number of subjects: 12
Study 21279864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 20208464 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental practice combined with physical practice (MP)
Number of subjects: 12
Study 20208464 — intervention group
Group type: COMPARATOR
Intervention: Physical practice with cognitive training (Cog)
Number of subjects: 12
Study 20208464 — intervention group
Group type: COMPARATOR
Intervention: No training (NOT)
Number of subjects: 12
Study 16679989 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration-aided static stretching (device turned on)
Number of subjects: 10